Drug Trial Radar · NCT03894579
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jun 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Jul 18, 2019
Primary completion
Dec 3, 2019
Study completion Dec 3, 2019
Sponsor
- Lead sponsor
- NKGen Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of four infusions of "SNK01" in subjects with plaque psoriasis. Secondary objective is preliminary efficacy of "SNK01" in subjects with plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
Study Product: SNK01Biological
SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint for safety is the dose-limiting toxicity (DLT)Time frame: From enrollment to end of treatment at 8 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Angeles
Tijuana, Estado de Baja California, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.